Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Adcirca
(United States) [Available] ,Alyq
(United States) [Available] ,Cialis
(United States) [Available] ,Tadliq
(United States) [Available]Synonyms :
tadalafil, tadalafilo
Class :
Phosphodiesterase-5 Enzyme Inhibitors
Brand Name :
Adcirca
(United States) [Available] ,Alyq
(United States) [Available] ,Cialis
(United States) [Available] ,Tadliq
(United States) [Available]Synonyms :
tadalafil, tadalafilo
Class :
Phosphodiesterase-5 Enzyme Inhibitors
Dosage forms & StrengthsÂ
Tablet (Cialis)Â
2.5mgÂ
5mgÂ
10mgÂ
20mgÂ
Tablet (Alyq, Adcirca)Â
20mg Â
Oral Suspension (Tadliq)Â
20mg/5mlÂ
5 mg orally once daily
If the treatment is carried on with tadalafil and finasteride, duration recommended is ≤26 weeks
10 mg orally initially as a single dose around half an hour before the anticipated sexual activity
The condition can be improved for 1.5 days after the single dose
Adjust the dose as required
May increase to 20 mg or decrease to 5 mg per dose
For daily dose- 2.5 mg initially once daily, disregard of sexual activity timing
Increase to 5 mg once daily based on the tolerability and efficacy
Pulmonary Arterial HypertensionÂ
40 mg orally once daily
May initiate with 20 mg daily and later increase to 40 mg 4 weeks later
Safety and efficacy are not foundÂ
Dosage forms & StrengthsÂ
Tablet (Cialis)Â
2.5mgÂ
5mgÂ
10mgÂ
20mgÂ
Tablet (Alyq, Adcirca)Â
20mg Â
Oral Suspension (Tadliq)Â
20mg/5mÂ
tadalafil is indicated for treatment of erectile dysfunction (ED)
Cialis/generic equivalent: No dosage adjustment is guaranteed singly based on age; however, a higher sensitivity towards medications in some geriatric people should be considered
Pulmonary Arterial HypertensionÂ
tadalafil is indicated for pulmonary arterial hypertension (PAH)
It improves the ability to exercise; studies establishing the efficacy included majorly the patients with NYHA Functional Class II – III symptoms. And the etiologies of heritable PAH (61%) are associated with PAH connective tissue diseases (23%)
May increase the vasodilatory effect when combined with Vasodilators
May increase the vasodilatory effect when combined with Vasodilators
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tadalafil
amyl nitrite: they may increase the vasodilatory effect when combined with Phosphodiesterase 5 Inhibitors
may enhance the hypotensive effect of Alpha1-Blockers
bunazosin (Not available in the United States)
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may increase the vasodilatory effect
may increase the vasodilatory effect
may increase the vasodilatory effect
may increase the vasodilatory effect
may increase the vasodilatory effect
may increase the vasodilatory effect
may increase the vasodilatory effect
may increase the vasodilatory effect
Phosphodiesterase 5 Inhibitors: they may increase the hypotensive effect when combined with blood viscosity reducing agents
Phosphodiesterase 5 Inhibitors: they may increase the hypotensive effect when combined with blood viscosity reducing agents
tadalafil: they may enhance the serum concentration of CYP3A4 Inhibitors
tadalafil: they may enhance the serum concentration of CYP3A4 Inhibitors
tadalafil: they may enhance the serum concentration of CYP3A4 Inhibitors
tadalafil: they may enhance the serum concentration of CYP3A4 Inhibitors
tadalafil: they may enhance the serum concentration of CYP3A4 Inhibitors
may have an increased hypotensive effect when combined with anti-hypertensive agents
may decrease the level of serum concentration
may decrease the level of serum concentration
may decrease the level of serum concentration
may decrease the level of serum concentration
May enhances the effects of the other by pharmacodynamic synergism
may enhance the effect of vasodilators
may enhance the effect of vasodilators
may enhance the effect of vasodilators
may enhance the effect of vasodilators
may enhance the effect of vasodilators
may increase the hypotensive effect of Blood Pressure Lowering Agents
may increase the hypotensive effect of Blood Pressure Lowering Agents
when nicorandil is combined or used concurrently with phosphodiesterase 5 inhibitors, it can lead to a decrease in blood pressure, which is called the synergic effect
Tadalafil relaxes blood vessel walls by increasing blood flow to penis and lungs. It inhibits PDE5 enzyme and enhances nitric oxide effects primarily used for treating ED and PAH and it improves erection ability in ED and improves exercise capacity in PAH.Â
Frequency definedÂ
>10%Â
Headache Â
Myalgia Â
Respiratory tract infection Â
Nasopharyngitis Â
Dyspepsia Â
Flushing Â
Back pain Â
Nausea Â
1-10%Â
Nasal congestion Â
Gastroesophageal reflux disease Â
Hypertension Â
Bronchitis Â
Genitourinary tract infection Â
<1%Â
AmnesiaÂ
Angina pectorisÂ
ArthralgiaÂ
Change in color visionÂ
Conjunctival hyperemiaÂ
DyspneaÂ
EpistaxisÂ
Black Box Warning:Â
NoneÂ
Tadalafil may be contraindicated with known allergies, nitrates or nitric oxide donors for chest pain or heart problems, vision loss, heart attacks or strokes within the past 6 months, and recreational drug use.Â
Pregnancy consideration:Â Â
Not recommended to be used in pregnant womenÂ
Breastfeeding warnings:Â Â
The drug is excreted in breastmilkÂ
Pregnancy category:Â
Pharmacology:Â
Pharmacodynamics:Â
Tadalafil is a selective inhibitor of cGMP-specific phosphodiesterase type 5 which increases cGMP concentration that leading to smooth muscle relaxation, vasodilation, and increased blood flow which improves erectile function in men with ED.Â
Pharmacokinetics:Â
AbsorptionÂ
Duration of action ≤36 hourÂ
Peak plasma time: Erectile dysfunction, 0.5-6 hr; PAH, 2-8 hrÂ
DistributionÂ
The protein-bound is 94%Â
The volume of distribution in the case of erectile dysfunction is 63 L, and for PAH is 77 LÂ
MetabolismÂ
The drug is metabolized in liver by CYP3A4Â
Elimination and ExcretionÂ
The half-life for erectile dysfunction is 15-17.5 hour; and for PAH is 35 hoursÂ
Total body clearance: Erectile dysfunction, 2.5 L/hr; PAH (not on bosentan), 1.6 L/hrÂ
The drug is excreted 61% in feces and 36% in urine Â
Administration:Â
Tadalafil is taken orally with or without food and should not be taken more than once daily. It is recommended to take it 30 minutes before sexual activity.Â
Patient information leafletÂ
Generic Name: TadalafilÂ
Pronounced: tuh·da·luh·filÂ
Why do we use Tadalafil?Â
Tadalafil is used to treat erectile dysfunction (ED) and the urinary symptoms of benign prostatic hyperplasia (BPH) in adult men. It also helps improve exercise capacity in people with pulmonary arterial hypertension (PAH).Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
